From the Neurogenetics Unit (S.N., M.G., E.M.V.), IRCCS Fondazione Santa Lucia, Rome; Department of Medicine and Surgery (S.N.), University of Salerno; National Center for Disease Prevention and Health Promotion (I.B., N.V.), National Institute of Health, Rome; Department of Molecular Medicine (M.G., A.C., V.S., E.M.V.), University of Pavia; IRCCS Stella Maris Foundation (R. Battini); Department of Clinical and Experimental Medicine (R. Battini), University of Pisa; Laboratory of Molecular Medicine (E.B., M.N., G.Z.), Unit of Neuromuscular and Neurodegenerative Disorders, Department of Neurosciences, and Laboratory of Medical Genetics (A.M.), IRCCS Bambino Gesù Children's Hospital, Rome; and Neuropsychiatry and Neurorehabilitation Unit (R. Borgatti, R.R.), Scientific Institute IRCCS Eugenio Medea, Bosisio Parini, Lecco, Italy.
Neurology. 2020 Feb 25;94(8):e797-e801. doi: 10.1212/WNL.0000000000008996. Epub 2020 Jan 22.
To estimate the prevalence of Joubert syndrome (JS) in Italy applying standards of descriptive epidemiology and to provide a molecular characterization of the described patient cohort.
We enrolled all patients with a neuroradiologically confirmed diagnosis of JS who resided in Italy in 2018 and calculated age and sex prevalence, assuming a Poisson distribution. We also investigated the correlation between proband chronological age and age at diagnosis and performed next-generation sequencing (NGS) analysis on probands' DNA when available.
We identified 284 patients with JS: the overall, female- and male-specific population-based prevalence rates were 0.47 (95% confidence interval [CI] 0.41-0.53), 0.41 (95% CI 0.32-0.49), and 0.53 (95% CI 0.45-0.61) per 100,000 population, respectively. When we considered only patients in the age range from 0 to 19 years, the corresponding population-based prevalence rates rose to 1.7 (95% CI 1.49-1.97), 1.62 (95% CI 1.31-1.99), and 1.80 (95% CI 1.49-2.18) per 100,000 population. NGS analysis allowed identifying the genetic cause in 131 of 219 screened probands. Age at diagnosis was available for 223 probands, with a mean of 6.67 ± 8.10 years, and showed a statistically significant linear relationship with chronological age ( = 0.79; < 0.001).
We estimated for the first time the age and sex prevalence of JS in Italy and investigated the patients' genetic profile. The obtained population-based prevalence rate was ≈10 times higher than that available in literature for children population.
应用描述性流行病学标准评估意大利杰特综合征(JS)的患病率,并对所描述的患者队列进行分子特征分析。
我们纳入了 2018 年居住在意大利且神经影像学确诊为 JS 的所有患者,并假设泊松分布计算了年龄和性别患病率。我们还调查了先证者实际年龄与诊断年龄之间的相关性,并在有条件时对先证者的 DNA 进行下一代测序(NGS)分析。
我们共鉴定出 284 例 JS 患者:总体、女性和男性人群患病率分别为 0.47(95%置信区间 [CI]:0.41-0.53)、0.41(95% CI:0.32-0.49)和 0.53(95% CI:0.45-0.61)/10 万人。当我们仅考虑 0 至 19 岁的患者时,相应的人群患病率上升至 1.7(95% CI:1.49-1.97)、1.62(95% CI:1.31-1.99)和 1.80(95% CI:1.49-2.18)/10 万人。对 219 例筛查先证者中的 131 例进行 NGS 分析后确定了遗传病因。我们获得了 223 例先证者的诊断年龄,平均为 6.67±8.10 岁,且与实际年龄呈显著线性关系( = 0.79; < 0.001)。
我们首次评估了意大利的 JS 年龄和性别患病率,并对患者的遗传特征进行了研究。所获得的人群患病率约为文献中儿童人群患病率的 10 倍。